- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02326142
A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth (TERM)
November 3, 2017 updated by: ObsEva SA
A Phase 2, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Safety and Efficacy of OBE001 After Oral Administration in Pregnant Women With Threatened Preterm Labour.
The primary objective of this study is to assess the efficacy of a single dose of OBE001, an oral oxytocin antagonist, given for up to 7 days to delay preterm birth by 7 days compared to placebo.
Study Overview
Detailed Description
The study will be a multi-centre, randomised, parallel group, double-blind, placebo-controlled study in pregnant women with threatened preterm labour between 34^0/7 and 35^6/7 weeks of gestation.
The study will be in 2 parts as follows:
- from screening until the day of delivery (including a treatment period up to seven days)
- a maternal and neonatal follow-up period from the day of delivery until 28 days post expected term date (or until 28 days post-delivery should this be later).
In addition, there will be an observational, safety follow-up of the infants for 2 years to evaluate developmental outcome.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussels, Belgium
-
Leuven, Belgium
-
Liege, Belgium
-
-
-
-
-
Bayreuth, Germany
-
Dusseldorf, Germany
-
Tuebingen, Germany
-
Ulm, Germany
-
-
-
-
-
Bialystok, Poland
-
Chorzow, Poland
-
Lodz, Poland
-
Ruda Slaska, Poland
-
Warsaw, Poland
-
-
-
-
-
Barcelona, Spain
-
El Palmar, Spain
-
Madrid, Spain
-
Vitoria - Gasteiz, Spain
-
Zaragoza, Spain
-
-
-
-
-
Basel, Switzerland
-
Bern, Switzerland
-
Geneva, Switzerland
-
Lausanne, Switzerland
-
-
-
-
-
Leeds, United Kingdom
-
London, United Kingdom
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Gestational age (GA) between 34^0/7 and 35^6/7 weeks.
- Subjects with symptoms of preterm labour.
- Subjects with a singleton pregnancy.
Exclusion Criteria:
- Foetal death in utero in current pregnancy or in previous pregnancy after gestational week 24 or expected high risk of foetal death in the current pregnancy.
- Any contraindications for the mother or the foetus to stop labour or prolong pregnancy or any maternal or foetal conditions likely to indicate iatrogenic delivery.
- Use of cervical cerclage or a pessary in situ in the current pregnancy.
- The Subject has any condition which in the opinion of the PI constitutes a risk or a contraindication for the participation of the subject in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo dispersible tablets for a single oral dose a day for up to 7 days.
|
Experimental: OBE001
|
OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
EFFICACY ENDPOINTS: Incidence of women delivering within 7 days post first dose
Time Frame: within 7 days of first dose
|
within 7 days of first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EFFICACY ENDPOINTS: Incidence of women delivering within 48 hours post first dose
Time Frame: within 48 hours of first dose
|
within 48 hours of first dose
|
|
EFFICACY ENDPOINTS: Incidence of women delivering before gestational age 37^0/7 weeks
Time Frame: up to 3 weeks post first dose
|
up to 3 weeks post first dose
|
|
EFFICACY ENDPOINTS: Progression of uterine contractions from pre-dose to 6 hours and 24 hours post first dose
Time Frame: up to 24 hours post first dose
|
Contractions measured by tocodynamometry.
|
up to 24 hours post first dose
|
EFFICACY ENDPOINTS: Assessment of maternal and foetal exposure to OBE001 (Maternal plasma concentrations of OBE001)
Time Frame: up to 7 weeks post first dose
|
Maternal plasma concentrations of OBE001 on Day 1 (2 hours post first dose), on Day 2 (pre-dose and 2 hours post-dose) on Day 3 (pre-dose), Day 7 (post-dose) and at the time of delivery.
Umbilical cord plasma concentration of OBE001 at the time of delivery.
|
up to 7 weeks post first dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SAFETY ENDPOINTS: Evaluation of the maternal safety of OBE001 (Maternal incidence of adverse events (AEs), treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory safety tests, 12-lead ECGs morphology or vital signs)
Time Frame: up to 28 days post expected term date
|
Maternal incidence of adverse events (AEs), treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory safety tests, 12-lead ECGs morphology or vital signs from Day 1 until 28 days after birth or term whichever is later.
|
up to 28 days post expected term date
|
SAFETY ENDPOINTS: Evaluation of the foetal safety of OBE001 (clinically significant changes in growth retardation and/or foetal heart rate monitoring and/or Amniotic Fluid Indices (AFI)
Time Frame: up to 14 days post first dose or birth whichever is earlier
|
Incidence of foetal distress as determined by clinically significant changes in growth retardation and/or foetal heart rate monitoring and/or Amniotic Fluid Indices (AFI) from Day 1 to Day 14 or birth, whichever is earlier
|
up to 14 days post first dose or birth whichever is earlier
|
SAFETY ENDPOINTS: Evaluation of the newborn neonatal morbidity
Time Frame: up to 28 days post expected term date
|
Incidence of infants experiencing adverse events assessed by vital signs, temperature, APGAR score, weight and head circumference at birth as well as measures of neonatal morbidity from birth until 28 days after birth or term whichever is later
|
up to 28 days post expected term date
|
SAFETY ENDPOINTS: Evaluation of infant neurodevelopmental outocme.
Time Frame: up to 2 years after birth
|
Incidence of infants with one or more Ages and Stages Questionnaire-3 domain score(s) below the cutoff at 6, 12, and 24 months, adjusted for gestational age.
|
up to 2 years after birth
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Actual)
October 1, 2016
Study Completion (Actual)
October 1, 2017
Study Registration Dates
First Submitted
December 22, 2014
First Submitted That Met QC Criteria
December 24, 2014
First Posted (Estimate)
December 25, 2014
Study Record Updates
Last Update Posted (Actual)
November 6, 2017
Last Update Submitted That Met QC Criteria
November 3, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-OBE001-016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Labor
-
Istanbul University - Cerrahpasa (IUC)CompletedPreterm Labor | Preterm Spontaneous Labor With Preterm Delivery | Preterm Labor With Preterm Delivery in Third TrimesterTurkey
-
Ain Shams UniversityRecruitingPreterm Labor With Preterm DeliveryEgypt
-
University Hospital, Strasbourg, FranceRecruitingPreterm Delivery | Threatened Preterm LaborFrance
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Konya Meram State HospitalRecruitingPregnancy Preterm | Preterm Labor Without DeliveryTurkey
-
University of Modena and Reggio EmiliaNot yet recruitingPreterm Labor With Preterm DeliveryItaly
-
e-Bio CorpRecruitingPreterm Labor | PreTerm Birth | Preterm Labor With Delivery NosUnited States
-
Shiraz University of Medical SciencesCompletedManaging Preterm Labor
-
Ain Shams Maternity HospitalCompletedThreatened Preterm LaborEgypt
-
Hospital Clinico Universitario de SantiagoFundación Ramón DomínguezWithdrawnThreatened Preterm Labor
Clinical Trials on OBE001
-
ObsEva SACompletedInfertilityPoland, United Kingdom, Spain, Belgium, Denmark, Czechia